Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study

Next Previous
Trial Profile

Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romidepsin (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
  • Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 01 Feb 2023 Interim Results assessing efficacy and safety of Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma published in the Leukemia
    • 13 Dec 2022 Results of sub-analysis evaluating the role of adding Romidepsin to CHOEP followed by high dose chemotherapy and SCT in newly diagnosis AITL and T-helper follicular lymphoma patients, presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 14 Dec 2021 Primary endpoint has not been met. (Progression Free Survival (PFS) of Ro-CHOEP-21 (Phase II endpoint))as per Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top